TY - JOUR
T1 - The Dutch Pancreas Biobank within the Parelsnoer Institute: A nationwide Biobank of pancreatic and periampullary diseases
AU - Strijker, Marin
AU - Gerritsen, Arja
AU - van Hilst, Jony
AU - Bijlsma, Maarten F.
AU - Bonsing, Bert A.
AU - Brosens, Lodewijk A.
AU - Bruno, Marco J.
AU - van Dam, Ronald M.
AU - Dijk, Frederike
AU - van Eijck, Casper H.
AU - Farina Sarasqueta, Arantza
AU - Fockens, Paul
AU - Gerhards, Michael F.
AU - Groot Koerkamp, Bas
AU - van der Harst, Erwin
AU - de Hingh, Ignace H.
AU - van Hooft, Jeanin E.
AU - Huysentruyt, Clément J.
AU - Kazemier, Geert
AU - Klaase, Joost M.
AU - van Laarhoven, Cornelis J.
AU - van Laarhoven, Hanneke W.
AU - Liem, Mike S.
AU - de Meijer, Vincent E.
AU - van Rijssen, L. Bengt
AU - van Santvoort, Hjalmar C.
AU - Suker, Mustafa
AU - Verhagen, Judith H.
AU - Verheij, Joanne
AU - Verspaget, Hein W.
AU - Wennink, Roos A.
AU - Wilmink, Johanna W.
AU - Molenaar, I. Quintus
AU - Boermeester, Marja A.
AU - Busch, Olivier R.
AU - Besselink, Marc G.
PY - 2018
Y1 - 2018
N2 - Objectives Large biobanks with uniform collection of biomaterials and associated clinical data are essential for translational research. The Netherlands has traditionally been well organized in multicenter clinical research on pancreatic diseases, including the nationwide multidisciplinary Dutch Pancreatic Cancer Group and Dutch Pancreatitis Study Group. To enable high-quality translational research on pancreatic and periampullary diseases, these groups established the Dutch Pancreas Biobank. Methods The Dutch Pancreas Biobank is part of the Parelsnoer Institute and involves all 8 Dutch university medical centers and 5 nonacademic hospitals. Adult patients undergoing pancreatic surgery (all indications) are eligible for inclusion. Preoperative blood samples, tumor tissue from resected specimens, pancreatic cyst fluid, and follow-up blood samples are collected. Clinical parameters are collected in conjunction with the mandatory Dutch Pancreatic Cancer Audit. Results Between January 2015 and May 2017, 488 patients were included in the first 5 participating centers: 4 university medical centers and 1 nonacademic hospital. Over 2500 samples were collected: 1308 preoperative blood samples, 864 tissue samples, and 366 follow-up blood samples. Conclusions Prospective collection of biomaterials and associated clinical data has started in the Dutch Pancreas Biobank. Subsequent translational research will aim to improve treatment decisions based on disease characteristics.
AB - Objectives Large biobanks with uniform collection of biomaterials and associated clinical data are essential for translational research. The Netherlands has traditionally been well organized in multicenter clinical research on pancreatic diseases, including the nationwide multidisciplinary Dutch Pancreatic Cancer Group and Dutch Pancreatitis Study Group. To enable high-quality translational research on pancreatic and periampullary diseases, these groups established the Dutch Pancreas Biobank. Methods The Dutch Pancreas Biobank is part of the Parelsnoer Institute and involves all 8 Dutch university medical centers and 5 nonacademic hospitals. Adult patients undergoing pancreatic surgery (all indications) are eligible for inclusion. Preoperative blood samples, tumor tissue from resected specimens, pancreatic cyst fluid, and follow-up blood samples are collected. Clinical parameters are collected in conjunction with the mandatory Dutch Pancreatic Cancer Audit. Results Between January 2015 and May 2017, 488 patients were included in the first 5 participating centers: 4 university medical centers and 1 nonacademic hospital. Over 2500 samples were collected: 1308 preoperative blood samples, 864 tissue samples, and 366 follow-up blood samples. Conclusions Prospective collection of biomaterials and associated clinical data has started in the Dutch Pancreas Biobank. Subsequent translational research will aim to improve treatment decisions based on disease characteristics.
UR - https://www.scopus.com/pages/publications/85044229350
UR - https://www.ncbi.nlm.nih.gov/pubmed/29521943
U2 - 10.1097/MPA.0000000000001018
DO - 10.1097/MPA.0000000000001018
M3 - Article
C2 - 29521943
SN - 0885-3177
VL - 47
SP - 495
EP - 501
JO - Pancreas
JF - Pancreas
IS - 4
ER -
SDG 3 Good Health and Well-being